Background
beta corona virus SARS-CoV-2, RBD
ACUTE RESPIRATORY INFECTION
In late 2019, the novel beta corona virus SARS-CoV-2 emerged from an animal reservoir into humans, causing an acute respiratory infection known as COVID-19 [One approach to combating pathogen outbreak, such as SARS-CoV-2, would be to use plasma from the convalescent patients [JMB2002–a human monoclonal antibody specifically binds to the RBD in S protein of SARS-CoV-2, was developed by Shanghai JiYu Pharmaceutical Technology Co. LTD, through a self-created FeiTai platform. It is a fully human IgG1 antibody containing N297A mutation in its constant region to attenuate Fc function [